Suppr超能文献

罕见表现的法布瑞氏病为“衰竭性”肥厚型心肌病。

Rare presentation of Fabry disease as 'burnt-out' hypertrophic cardiomyopathy.

机构信息

Division of Cardiology, Bristol Heart Institute, Bristol, UK.

Division of Cardiology, Bristol Heart Institute, Bristol, UK

出版信息

BMJ Case Rep. 2021 Sep 3;14(9):e243604. doi: 10.1136/bcr-2021-243604.

Abstract

We herein report the case of a 53-year-old man who was historically diagnosed with hypertrophic cardiomyopathy (HCM) and was lost to follow-up, before presenting with end-stage heart failure. This was initially suspected as dilated cardiomyopathy and then 'burnt-out phase' of HCM but subsequently the underlying diagnosis was Fabry disease. Fabry disease is an uncommon lysosomal-storage disease due to reduced or absent activity of the alpha-galactosidase A enzyme. Cardiac involvement most frequently comprises left ventricular hypertrophy. Early treatment of the underlying condition with enzyme replacement therapy may prevent the progression to end-stage heart failure. Fabry disease should be considered in all patients presenting with a clinical phenotype of HCM and a historical diagnosis should be re-evaluated in light of new diagnostic tools. Untreated Fabry can progress to a 'burnt out' phase, whereby initial hypertrophy undergoes eccentric remodelling to a dilated, severely impaired left ventricle.

摘要

我们在此报告一例 53 岁男性病例,该患者既往被诊断为肥厚型心肌病(HCM),失访后出现终末期心力衰竭。最初怀疑为扩张型心肌病,随后为 HCM 的“耗竭期”,但随后的潜在诊断为法布瑞病。法布瑞病是一种罕见的溶酶体贮积病,由于α-半乳糖苷酶 A 酶的活性降低或缺失。心脏受累最常见的表现为左心室肥厚。早期用酶替代疗法治疗潜在疾病可能阻止疾病进展为终末期心力衰竭。对于所有表现出 HCM 临床表型的患者都应考虑法布瑞病,并且应根据新的诊断工具重新评估既往诊断。未经治疗的法布瑞病可能进展为“耗竭期”,最初的肥厚会发生偏心重塑,导致扩张性、严重受损的左心室。

相似文献

1
Rare presentation of Fabry disease as 'burnt-out' hypertrophic cardiomyopathy.
BMJ Case Rep. 2021 Sep 3;14(9):e243604. doi: 10.1136/bcr-2021-243604.
2
Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.
Am J Med. 2018 Feb;131(2):200.e1-200.e8. doi: 10.1016/j.amjmed.2017.09.010. Epub 2017 Sep 21.
3
Fabry disease and the heart.
Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):195-204. doi: 10.1016/j.beem.2014.10.003. Epub 2014 Oct 16.
4
Cardiac challenges in patients with Fabry disease.
Int J Cardiol. 2010 May 14;141(1):3-10. doi: 10.1016/j.ijcard.2009.08.002. Epub 2009 Aug 31.
5
Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Herz. 2002 Nov;27(7):699-702. doi: 10.1007/s00059-002-2429-9.
6
Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
Heart. 2015 Feb;101(4):287-93. doi: 10.1136/heartjnl-2014-306278. Epub 2014 Nov 7.
7
Late-onset Fabry disease: the cardiac sequela.
BMJ Case Rep. 2022 Jun 9;15(6):e247917. doi: 10.1136/bcr-2021-247917.
9
Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy.
J Cardiol. 2017 Jan;69(1):302-307. doi: 10.1016/j.jjcc.2016.05.014. Epub 2016 Aug 21.
10
The heart in Anderson Fabry disease.
Z Kardiol. 2002 Oct;91(10):786-95. doi: 10.1007/s00392-002-0848-5.

引用本文的文献

1
Concurrent fabry disease and immunoglobulin a nephropathy: a case report.
BMC Nephrol. 2023 Nov 1;24(1):324. doi: 10.1186/s12882-023-03282-3.

本文引用的文献

1
Fabry disease with early-onset ventricular dilation: A case report.
Medicine (Baltimore). 2020 Sep 25;99(39):e22326. doi: 10.1097/MD.0000000000022326.
2
Diagnosing burned-out hypertrophic cardiomyopathy: Daughter's phenotype solidifies father's diagnosis.
J Cardiol Cases. 2014 Nov 25;11(3):78-80. doi: 10.1016/j.jccase.2014.10.010. eCollection 2015 Mar.
3
Anderson-Fabry disease in heart failure.
Biophys Rev. 2018 Aug;10(4):1107-1119. doi: 10.1007/s12551-018-0432-5. Epub 2018 Jun 16.
4
A Review of Fabry Disease.
Skin Therapy Lett. 2018 Mar;23(2):4-6.
5
7
Fabry disease and the heart.
Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):195-204. doi: 10.1016/j.beem.2014.10.003. Epub 2014 Oct 16.
9
Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis.
Genet Mol Biol. 2012 Dec;35(4 (suppl)):947-54. doi: 10.1590/s1415-47572012000600009. Epub 2012 Dec 18.
10
Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging.
Circ Heart Fail. 2012 Jul 1;5(4):535-46. doi: 10.1161/CIRCHEARTFAILURE.112.967026.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验